Dr. Induru Discusses Other Mutations in Lung Cancer | OncLive

Dr. Induru Discusses Other Mutations in Lung Cancer

November 21, 2017

Raghava R. Induru, MD, medical oncologist, Levine Cancer Institute, discusses other mutations in lung cancer.

Raghava R. Induru, MD, medical oncologist, Levine Cancer Institute, discusses other mutations in lung cancer.

EGFR, ALK, and ROS1, are the most well-known molecular subtypes of lung cancer, and have been used to develop effective treatments, but there are other targets that may help guide treatment.

Of these other targets, BRAF mutations and NTRK mutations are most notable, says Induru. The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) is FDA approved for BRAF-mutated tumors, and entrectinib is showing promise in NTRK-mutated tumors.


x